CHO-K1/Human GPR52 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0246A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The GPR52 (G protein-coupled receptor 52) is an orphan G protein-coupled receptor that is predominantly and highly expressed in the brain. It is most abundantly found in the striatum of the brain (including the caudate nucleus and putamen) and is also present in areas like the cortex. It functions as a Gs/olf-coupled receptor, regulating intracellular cAMP signaling pathways. Studies suggest that stimulating GPR52 activity might be beneficial for treating psychiatric disorders like schizophrenia, whereas inhibiting its activity could offer a potential therapeutic approach for Huntington's disease. Accordingly, an orally available GPR52 agonist, HTL0048149, has advanced into Phase I clinical trials for schizophrenia.
Screeningbio’s CHO-K1/Human GPR52 cell line overexpress GPR52 receptor and is designed to detect increases in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF Gs cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | GPR52 |
Accession Number | NM_005684 (Hs) |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The GPR52 (G protein-coupled receptor 52) is an orphan G protein-coupled receptor that is predominantly and highly expressed in the brain.
It is most abundantly found in the striatum of the brain (including the caudate nucleus and putamen) and is also present in areas like the cortex. It functions as a Gs/olf-coupled receptor, regulating intracellular cAMP signaling pathways.
Studies suggest that stimulating GPR52 activity might be beneficial for treating psychiatric disorders like schizophrenia, whereas inhibiting its activity could offer a potential therapeutic approach for Huntington's disease. Accordingly, an orally available GPR52 agonist, HTL0048149, has advanced into Phase I clinical trials for schizophrenia.